A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab)
The company EirGenix, Inc is enrolling patients into the clinical trial investigating A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers.
This trial is a single-center, single-dose, double-blind, parallel-group, randomized, 3-arm PK trial in healthy male volunteers comparing a biosimilar pertuzumab (EG1206A) to a single intravenous (i.v.) infusion to both European Union (EU) and United States of America (US) reference products.
The trial is designed to enroll Male 18 Years to 55 Years and is being conducted in the CRS Clinical Research Services Berlin GmbH, Berlin, Germany.
The study start date is May 16, 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05471648.
